About one year ago, disease-modifying antibody therapies for Alzheimer’s disease became available in clinical practice, marking a fundamental shift in neurological medicine. Experts from the Deutsche Gesellschaft für Neurologie e.V. have now evaluated the first real-world experiences with these targeted treatments in German memory clinics. The evaluation encompasses drug safety profiles, patient selection criteria, recent decisions by official health authorities, and novel diagnostic blood markers. Understanding these developments helps international patients and their families navigate treatment options currently offered in specialized medical centers in Germany.
Targeted Biologic Mechanisms and Clinical Trial Results

Alzheimer’s disease is a progressive neurodegenerative disorder that gradually impairs memory, cognitive functions, and the ability to perform daily tasks independently. Historically, medical care relied primarily on symptomatic medications such as acetylcholinesterase inhibitors, which temporarily ease cognitive burdens without halting the underlying pathological degeneration. In contrast, disease-modifying therapies aim directly at the primary biological hallmarks of the condition, specifically the abnormal accumulation of amyloid protein plaques in brain tissue. Clearing these extracellular toxic deposits represents a distinct therapeutic concept aimed at slowing down the overall pace of cognitive decline.
The monoclonal antibodies Lecanemab and Donanemab were developed specifically to bind to amyloid structures and facilitate their removal from brain tissue by the immune system. Pivotal phase three clinical trials evaluated the efficacy of these targeted biologics in large groups of patients with early symptomatic stages of the disease. In these randomized controlled studies, researchers observed a statistically significant reduction in the rate of cognitive and functional deterioration compared to placebo controls. These clinical findings were published in prominent peer-reviewed medical journals including N Engl J Med and JAMA.
Data from the landmark trial published in N Engl J Med demonstrated that Lecanemab slowed cognitive and functional decline by approximately 27 percent over an 18-month treatment period. Similarly, clinical evidence published in JAMA for Donanemab showed a 22 percent slowing of disease progression at 76 weeks across the overall study population. In a prespecified subgroup of patients presenting with low-to-medium tau protein pathology, Donanemab demonstrated an even higher slowdown rate of approximately 35 percent. These quantitative results confirm that targeted clearance of amyloid plaques exerts a measurable impact on the progression of symptoms.
Reflecting on these clinical figures, Prof. Dr. Özgür Onur from Köln, spokesperson for the Demenzen commission of the DGN, emphasized the realistic perspective required when evaluating these outcomes. He noted that while treatment effects remain modest and higher efficacy remains an ultimate goal, having drugs that alter disease course is a crucial milestone. For affected individuals and their families, the primary clinical relevance lies in extending the timeframe during which patients can maintain daily independence. Long-term observational research continues to analyze how these recorded slowdowns manifest over extended periods of time beyond initial clinical trials.
Safety Profiles and Clinical Experience in Specialized Centers

The clinical implementation of amyloid-targeting antibodies requires continuous vigilance regarding potential adverse effects. The primary safety concern centers on Amyloid-related Imaging Abnormalities, known as ARIA, which present as local brain swelling or signs of microhemorrhage on magnetic resonance imaging scans. While many occurrences of ARIA remain asymptomatic and resolve spontaneously, severe neurological complications can arise in a subset of treated individuals. Consequently, safe clinical administration demands meticulous patient selection, thorough baseline risk assessment, and strictly scheduled follow-up imaging protocols.
In Germany, treatment with monoclonal antibodies is conducted exclusively within specialized memory centers and qualified neurological practices equipped with high-field magnetic resonance imaging technology. Rigorous diagnostic evaluation prior to therapy ensures that only suitable candidates without contraindications receive the treatment. Routine monitoring protocols include regular magnetic resonance imaging scans performed at specific intervals during the first months of therapy to detect any signs of ARIA early. This structured clinical setup is designed to identify asymptomatic imaging changes before any symptomatic brain swelling or bleeding develops.
Prof. Dr. Özgür Onur reported encouraging feedback from German memory clinics (Gedächtnisambulanzen) after the first year of real-world clinical application. Initial concerns regarding severe side effects were high, yet practical safety outcomes in routine care have proven slightly better than initially anticipated. This favorable real-world experience is largely attributed to strict patient selection criteria and meticulous protocol adherence before and during antibody administration. International observational studies published in Alzheimers Dement and JAMA Neurol further support these findings, demonstrating no unexpected safety signals beyond the known risks identified in controlled approval trials.
Benefit Assessment by German Health Authorities and Regulatory Standards

Considerable public and medical discussion emerged in Germany following decisions issued by the Gemeinsamer Bundesausschuss, abbreviated as G-BA. In its early benefit evaluations for both Lecanemab and Donanemab, the G-BA concluded that an added clinical benefit over existing standard therapies was not sufficiently proven. This conclusion appeared paradoxical to many patients and clinicians aware of the positive primary results from European drug approval trials. To understand this outcome, one must distinguish between European market authorization criteria and the national benefit assessment framework enforced in Germany.
European drug approval focuses strictly on assessing whether a therapeutic agent demonstrates efficacy, safety, and acceptable quality to establish a positive benefit-risk ratio. In contrast, the benefit assessment by the G-BA evaluates whether a newly approved drug provides a superior, patient-relevant benefit when directly compared to an established standard comparator therapy. The original design of the international phase three approval trials was not constructed to answer the specific comparative questions required by German health economic legislation. As a result, methodological differences in data selection led to divergent conclusions between licensing authorities and benefit evaluators.
For the official German assessment, evaluators included only the subset of trial participants meeting narrow European licensing criteria and subsequently split them into distinct cohorts. Patients with mild cognitive impairment (MCI) were evaluated against the comparator standard of watchful waiting, whereas patients with mild dementia were evaluated against acetylcholinesterase inhibitors. Furthermore, only trial participants whose concomitant medications aligned strictly with these pre-defined standards were included in the final statistical analysis. This step-by-step restriction significantly reduced the evaluated patient sample size, resulting in insufficient statistical power to prove added benefit under the specific requirements of the G-BA.
Prof. Dr. Özgür Onur explained that while the methodological rigor of the G-BA assessment can be understood, clinicians may question whether these criteria fully reflect clinical progress in complex neurological diseases. Importantly, the rulings of the G-BA do not invalidate or revoke the official market approval of Lecanemab and Donanemab in Germany or Europe. Instead, these benefit evaluations serve primarily as the regulatory basis for negotiating formal reimbursement amounts between pharmaceutical manufacturers and statutory health insurance funds. Clinical access remains governed by medical indications, individual doctor-patient consultations, and specialized center protocols.
Advanced Blood Biomarkers and Future Presymptomatic Interventions

Alongside therapeutic advances, diagnostic methodology for Alzheimer’s disease is undergoing a major technological transformation. Blood-based biomarkers, particularly phosphorylated tau protein p-tau217, now offer highly sensitive indicators of Alzheimer-related biological changes in brain tissue. Historically, confirming amyloid pathology required invasive cerebrospinal fluid collection via lumbar puncture or expensive positron emission tomography scans like amyloid-PET. High-performance blood tests allow earlier and less burdensome diagnostic evaluation for patients presenting with cognitive symptoms in specialized memory centers.
Despite these technological achievements, expert professional societies including the DGN caution against using blood biomarkers as a broad screening tool for asymptomatic populations. A positive biomarker result indicates biological pathology but does not guarantee that an individual will inevitably develop clinical dementia during their lifetime. Furthermore, medical consensus has not yet established clear therapeutic interventions for individuals who show biological markers without any overt cognitive complaints. Consequently, official guidelines recommend using p-tau217 tests strictly within targeted diagnostic workups for individuals experiencing documented cognitive decline.
Looking to the future, blood tests and advanced imaging may facilitate initiating disease-modifying therapies prior to the onset of recognizable clinical symptoms. Pathological changes in brain tissue typically commence many years before memory loss and cognitive impairment become clinically observable. Ongoing international clinical trial programs are currently investigating whether presymptomatic antibody treatment can prevent or delay clinical symptom onset. Key ongoing studies include AHEAD 3-45 evaluating Lecanemab, TRAILBLAZER-ALZ 3 evaluating Donanemab, and the upcoming PrevenTRON study investigating Trontinemab.
If presymptomatic trials demonstrate clinical efficacy, targeted screening of high-risk populations could become a reality in future preventative neurology. Prof. Dr. Özgür Onur highlighted that treating disease before symptoms manifest would represent another major step forward in Alzheimer care. However, he emphasized that decisive therapeutic breakthroughs will likely arise from combining multiple therapeutic strategies rather than relying on a single agent. Drawing parallels to Multiple Sklerose, where successive therapeutic innovations transformed patient outcomes over decades, ongoing research aims to refine existing antibody treatments and develop novel multi-target interventions.